Skip to content
Sign in

AGIO · NASDAQ

Agios Pharmaceuticals (AGIO) Stock Price & Fundamentals

$528.57+0.78%+$4.11End-of-day price as of Oct 9, 2026

Agios Pharmaceuticals (AGIO) closed at $528.57 on Oct 9, 2026, up 0.78% from the previous close of $524.46.

Share price, past year

1Y +16.04%

52-week range $451.58 – $567.09. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$528.57
Sep 30, 2026$517.95
Aug 31, 2026$537.20
Jul 31, 2026$505.08
Jun 30, 2026$519.69
May 29, 2026$541.18
Apr 30, 2026$551.98
Mar 31, 2026$509.92
Feb 27, 2026$500.16
Jan 30, 2026$482.13
Dec 31, 2025$481.88
Nov 28, 2025$476.47
Oct 31, 2025$473.33

Key statistics

Market cap
$31.51B
P/E (TTM)
—
EPS (TTM)
−$7.02
Revenue (TTM)
$98.34M
Net income (TTM)
−$411.29M
Shares outstanding
59.6M
Dividend yield
—
52-week range
$451.58 – $567.09

Agios Pharmaceuticals's market cap is $31.51B, based on a share price of $528.57 and 59.6M shares outstanding as of Jun 30, 2026.

Financials

Agios Pharmaceuticals reported revenue of $54.03M for fiscal 2025, up 48.03% from fiscal 2024.

Agios Pharmaceuticals reported a net loss of $412.78M in fiscal 2025.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Agios Pharmaceuticals annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$54.03M+48.0%−$412.78M−764.0%−$7.12−$377.29M
FY2024ended Dec 31, 2024$36.50M+36.1%$673.73M1,845.9%$11.64−$391.53M
FY2023ended Dec 31, 2023$26.82M+88.4%−$352.09M−1,312.6%−$6.33−$297.06M
FY2022ended Dec 31, 2022$14.24M—−$231.80M−1,627.8%−$4.23−$314.36M
FY2021ended Dec 31, 2021$0.00—$1.60B—$26.55−$413.06M
FY2020ended Dec 31, 2020$0.00−100.0%−$327.37M—−$4.74−$304.87M
FY2019ended Dec 31, 2019$117.91M+24.9%−$411.47M−349.0%−$6.86−$382.65M
FY2018ended Dec 31, 2018$94.39M+119.5%−$346.03M−366.6%−$6.03−$311.41M
FY2017ended Dec 31, 2017$43.01M−38.5%−$314.67M−731.6%−$6.75−$289.86M
FY2016ended Dec 31, 2016$69.89M—−$198.47M−284.0%−$5.07$28.65M
Agios Pharmaceuticals quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$44.75M−$100.70M−$1.69
Q1 FY2026ended Mar 31, 2026$20.75M−$99.11M−$1.69
Q4 FY2025ended Dec 31, 2025$19.97M−$108.04M−$1.86
Q3 FY2025ended Sep 30, 2025$12.88M−$103.43M−$1.78
Q2 FY2025ended Jun 30, 2025$12.46M−$112.02M−$1.93
Q1 FY2025ended Mar 31, 2025$8.73M−$89.29M−$1.55
Q4 FY2024ended Dec 31, 2024$10.73M−$96.52M−$1.44
Q3 FY2024ended Sep 30, 2024$8.96M$947.92M$16.22

Company profile

Name
Agios Pharmaceuticals, Inc.
Ticker
AGIO
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
88 Sidney Street, Cambridge, MA 02139
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001439222

Recent SEC filings

Frequently asked questions

What is Agios Pharmaceuticals's stock price?

Agios Pharmaceuticals (AGIO) closed at $528.57 on Oct 9, 2026, up 0.78% from the previous close of $524.46.

What is Agios Pharmaceuticals's market cap?

Agios Pharmaceuticals's market cap is $31.51B, based on a share price of $528.57 and 59.6M shares outstanding as of Jun 30, 2026.

How much revenue does Agios Pharmaceuticals make?

Agios Pharmaceuticals reported revenue of $54.03M for fiscal 2025, up 48.03% from fiscal 2024.

Does Agios Pharmaceuticals pay a dividend?

Agios Pharmaceuticals's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Agios Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures